Avanos Medical Reports Significant Progress in Q4 and Full-Year 2025 Financial Results

Avanos Medical Reports Fourth Quarter and Full-Year 2025 Results

Avanos Medical, Inc. (NYSE: AVNS) shared its financial results for both the fourth quarter and full year ending December 31, 2025. The reporting highlights the company's strategic priorities and progress in the face of a challenging economic landscape.

Performance Highlights

The company saw total net sales reach $180.9 million in Q4, marking a slight increase of 0.7% from the same period last year. Notably, operating income turned around to a positive $2.5 million from a staggering loss of $418.5 million in Q4 of 2024 due to significant reorganization efforts.

In terms of net loss, Avanos reported $1.3 million, a drastic improvement from the previous year's loss of $397 million. Adjusted earnings depict a robust performance as well, with earnings per share standing at $0.03 compared to the devastating $8.63 loss per share recorded last year.

David Pacitti, the CEO of Avanos, expressed his satisfaction with the results, indicating that meaningful progress has been achieved on the company’s strategic objectives. The organic growth of 6% in key segments was particularly encouraging and is expected to position the company favorably for future endeavors.

Specialty Nutrition Systems Segment

The Specialty Nutrition Systems (SNS) segment was a standout performer, achieving net sales of $115.1 million in the fourth quarter. This reflects a growth rate of 8.7% compared to the prior year. Operating income for SNS reached $20.5 million, representing about 17.8% of net sales, although this is down by $4.5 million compared to the prior year.

Pain Management Segment

Meanwhile, the Pain Management and Recovery (PMR) segment saw net sales increase to $61.6 million, a growth of 1.3%. This segment also recorded an improvement in operating income, rising to $5.2 million from $3.9 million in the previous year.

For the full year of 2025, Avanos reported net sales of $701.2 million, reflecting an increase of 1.9% from $687.8 million in 2024. Furthermore, the operating loss decreased significantly to $61.6 million from a staggering $396.2 million the year prior. Adjusted EBITDA for 2025 was reported at $86.8 million, although this is a decrease from $107.6 million in 2024.

Strategic Initiatives and Cost Management

Amid these operational changes, Avanos has been diligently implementing cost management initiatives that are on track to provide additional annual savings between $15 to $20 million by the end of 2026. The company is also continuing to work on their tariff mitigation strategies, which have begun to yield positive effects.

Additionally, the company launched significant strategic transformations, included selling its HA product line to Channel-Markers Medical, LLC in a move designed to streamline operations and focus on its core areas of strength within Specialty Nutrition Systems and Pain Management segments.

Outlook for 2026

Looking forward, Avanos anticipates net sales in the range of $700 million to $720 million for 2026, with adjusted diluted earnings per share projected between $0.90 and $1.10. This positive trajectory reflects the company's commitment to innovation and adaptability in navigating the evolving healthcare markets.

As the financial year unfolds, Avanos Medical stands poised to capitalize on its recent gains, driving forward initiatives designed to enhance its portfolio and deliver superior healthcare solutions worldwide. Stakeholders can look forward to continued updates and performance reports as the company progresses through 2026 and beyond.